HER2-POSITIVE BREAST CANCER

This early-phase study tests a new dendritic cell vaccine given directly into the spinal fluid for people with triple-negative or HER2-positive breast cancer that has spread to the lining of the brain (leptomeningeal disease). The main goal is to find the highest safe dose. About…

This study tests whether a combination of two targeted drugs (trastuzumab and pertuzumab) plus hormone therapy can prevent breast cancer from returning after surgery. It includes about 393 people with early-stage, hormone receptor-positive, HER2-positive breast cancer that has no…

This study tests a new drug (TVB-2640) combined with standard therapies in people with HER2-positive breast cancer that has spread and stopped responding to treatment. The goal is to see if this combination can shrink tumors or slow the disease. The trial involves 17 adults with …

This study tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed. First, patients receive a strong drug called trastuzumab deruxtecan. Then, they switch to a maintenance combination of two other drugs (trastuzumab and pertuzum…

This study was designed to see if giving less chemotherapy before surgery, followed by targeted therapy based on how the tumor responded, could work well for people with early-stage HER2-positive breast cancer. The goal was to maintain high survival rates while reducing side effe…

This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help eliminate more cancer cells before surgery in women with early-stage HER2-positive breast cancer. About 90 participants will receive either…

This study looks at whether people with HER2-positive metastatic breast cancer who have had an excellent response to treatment (cancer controlled for 3+ years) can safely stop their anti-HER2 therapy. Researchers will monitor how long it takes for the cancer to progress in those …

This study tests whether adding tucatinib (a targeted pill) to standard T-DM1 therapy works better than T-DM1 alone for people with advanced HER2-positive breast cancer that has spread or cannot be removed surgically. About 466 participants will randomly receive either tucatinib …

This phase 3 study tests whether a new drug, DB-1303, works better than the current standard T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. About 228 adults who have already tried trastuzumab and a taxane will be randomly assign…

This study looks at whether some women with HER2-positive early breast cancer can be treated with just the targeted drugs pertuzumab and trastuzumab (PHESGO™) without chemotherapy. Researchers use specific markers to pick patients whose tumors depend heavily on HER2. The goal is …

This study tests a new drug called ZN-A-1041, taken as a capsule, for people with advanced HER2-positive solid tumors (cancers that have spread). The drug is given alone or with other standard cancer medicines. The main goals are to check safety, find the best dose, and see if it…

This study tests whether a newer drug, Margetuximab, works better than the standard drug Trastuzumab when combined with chemotherapy and another targeted therapy before surgery for stage II-III HER2-positive breast cancer. About 174 participants will receive one of the two drug c…

This study tests whether giving two drugs (taxotere and trastuzumab) before surgery can eliminate all signs of invasive cancer in Nigerian women with HER2-positive breast cancer. About 53 women with stage II or III breast cancer who have not had prior chemotherapy will receive th…

This phase 3 trial compares a new drug, A166, to the standard treatment T-DM1 in 365 adults with HER2-positive breast cancer that has spread or cannot be removed. Participants must have already tried trastuzumab and a taxane. The main goal is to see if A166 delays cancer growth b…

This early-stage study is testing a new drug called ELVN-002 combined with trastuzumab (and sometimes chemotherapy) in adults with advanced HER2-positive solid tumors, including breast, colorectal, and gastric cancers. The main goals are to find the safest dose and understand sid…

This study tests a less intense chemotherapy combination for people with early-stage HER2-positive breast cancer. The goal is to see if a milder regimen (paclitaxel, trastuzumab, and pertuzumab) can clear the cancer before surgery as effectively as the standard stronger regimen, …

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard stereotactic radiation can better control brain metastases that are at higher risk of coming back after radiation alone. About 134 adults with cancers like melanoma, lung, breast, or colorectal cance…

This early-phase study tests a new treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The treatment involves taking the patient's own immune cells, modifying them to recognize and attack HER2-positive cancer cells,…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab and pertuzumab) can delay cancer growth in people with advanced HER2-positive breast cancer that has spread. About 654 participants will receive either tucatinib or a placebo pill, along with the …

This study looks at whether women (and men) age 40+ with early-stage, low-risk HER2+ breast cancer can safely skip radiation after breast-conserving surgery if they have already received chemotherapy and HER2-targeted therapy. About 1,300 participants will be randomly assigned to…

This small pilot study tested whether a special PET scan using a radioactive tracer can predict how well patients with advanced HER2-positive breast cancer respond to the drug ado-trastuzumab emtansine (T-DM1). Ten women with cancer that had spread to other parts of the body rece…

This study tests two vaccines designed to prevent breast cancer from returning in people who have already been treated for HER2-positive breast cancer. About 119 participants who had chemotherapy and surgery but still had cancer cells left will receive one of the vaccines. The go…

This study planned to test whether a special type of PET/MRI scan could detect early signs that targeted therapy is working in people with stage IV HER2+ breast cancer. It was designed for adults aged 18 to 75 with HER2+ metastatic breast cancer. However, the study was withdrawn …

This study looks at how the area around a tumor changes in HER2-positive breast cancer patients during chemotherapy before surgery. Researchers will take samples before, during, and after treatment to track these changes. The goal is to better understand how the tumor responds to…

This study looks at how well a cardiopulmonary exercise test (CPET) can measure oxygen use in women with HER2-positive breast cancer who have mild heart problems from their cancer treatment. The goal is to see if this test can help predict how their heart and lungs will handle co…